Gerald A Deehan1, Sheketha R Hauser2, R Aaron Waeiss2, Christopher P Knight2, Jamie E Toalston2, William A Truitt2, William J McBride2, Zachary A Rodd2. 1. Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Neuroscience Research Building, 320 West 15th St, Indianapolis, IN, 46202-2266, USA. gdeehan@iupui.edu. 2. Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Neuroscience Research Building, 320 West 15th St, Indianapolis, IN, 46202-2266, USA.
Abstract
RATIONALE: The co-abuse of ethanol (EtOH) and nicotine (NIC) increases the likelihood that an individual will relapse to drug use while attempting to maintain abstinence. There is limited research examining the consequences of long-term EtOH and NIC co-abuse. OBJECTIVES: The current experiments determined the enduring effects of chronic EtOH, NIC, or EtOH + NIC intake on the reinforcing properties of NIC and glutamate (GLU) activity within the mesocorticolimbic (MCL) system. METHODS: Alcohol-preferring (P) rats self-administered EtOH, Sacc + NIC, or EtOH + NIC combined for 10 weeks. The reinforcing properties of 0.1-3.0 μM NIC within the nucleus accumbens shell (AcbSh) were assessed following a 2-3-week drug-free period using intracranial self-administration (ICSA) procedures. The effects of EtOH, Sacc, Sacc + NIC, or EtOH + NIC intake on extracellular levels and clearance of glutamate (GLU) in the medial prefrontal cortex (mPFC) were also determined. RESULTS: Binge intake of EtOH (96-100 mg%) and NIC (21-27 mg/mL) were attained. All groups of P rats self-infused 3.0 μM NIC directly into the AcbSh, whereas only animals in the EtOH + NIC co-abuse group self-infused the 0.3 and 1.0 μM NIC concentrations. Additionally, self-administration of EtOH + NIC, but not EtOH, Sacc or Sacc + NIC, resulted in enduring increases in basal extracellular GLU levels in the mPFC. CONCLUSIONS: Overall, the co-abuse of EtOH + NIC produced enduring neuronal alterations within the MCL which enhanced the rewarding properties of NIC in the AcbSh and elevated extracellular GLU levels within the mPFC.
RATIONALE: The co-abuse of ethanol (EtOH) and nicotine (NIC) increases the likelihood that an individual will relapse to drug use while attempting to maintain abstinence. There is limited research examining the consequences of long-term EtOH and NIC co-abuse. OBJECTIVES: The current experiments determined the enduring effects of chronic EtOH, NIC, or EtOH + NIC intake on the reinforcing properties of NIC and glutamate (GLU) activity within the mesocorticolimbic (MCL) system. METHODS:Alcohol-preferring (P) rats self-administered EtOH, Sacc + NIC, or EtOH + NIC combined for 10 weeks. The reinforcing properties of 0.1-3.0 μM NIC within the nucleus accumbens shell (AcbSh) were assessed following a 2-3-week drug-free period using intracranial self-administration (ICSA) procedures. The effects of EtOH, Sacc, Sacc + NIC, or EtOH + NIC intake on extracellular levels and clearance of glutamate (GLU) in the medial prefrontal cortex (mPFC) were also determined. RESULTS: Binge intake of EtOH (96-100 mg%) and NIC (21-27 mg/mL) were attained. All groups of P rats self-infused 3.0 μM NIC directly into the AcbSh, whereas only animals in the EtOH + NIC co-abuse group self-infused the 0.3 and 1.0 μM NIC concentrations. Additionally, self-administration of EtOH + NIC, but not EtOH, Sacc or Sacc + NIC, resulted in enduring increases in basal extracellular GLU levels in the mPFC. CONCLUSIONS: Overall, the co-abuse of EtOH + NIC produced enduring neuronal alterations within the MCL which enhanced the rewarding properties of NIC in the AcbSh and elevated extracellular GLU levels within the mPFC.
Authors: Roberto I Melendez; Zachary A Rodd-Henricks; Eric A Engleman; Ting-Kai Li; William J McBride; James M Murphy Journal: Alcohol Clin Exp Res Date: 2002-03 Impact factor: 3.455
Authors: William A Truitt; Sheketha R Hauser; Gerald A Deehan; Jamie E Toalston; Jessica A Wilden; Richard L Bell; William J McBride; Zachary A Rodd Journal: Psychopharmacology (Berl) Date: 2014-08-26 Impact factor: 4.530
Authors: Thomas S Hnasko; Nao Chuhma; Hui Zhang; Germaine Y Goh; David Sulzer; Richard D Palmiter; Stephen Rayport; Robert H Edwards Journal: Neuron Date: 2010-03-11 Impact factor: 17.173
Authors: Sheketha R Hauser; Amy L Bracken; Gerald A Deehan; Jamie E Toalston; Zheng-Ming Ding; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd Journal: Addict Biol Date: 2013-03-18 Impact factor: 4.280
Authors: Zheng-Ming Ding; Zachary A Rodd; Eric A Engleman; Jason A Bailey; Debomoy K Lahiri; William J McBride Journal: Addict Biol Date: 2012-12-14 Impact factor: 4.280
Authors: Andrew Holmes; Paul J Fitzgerald; Kathryn P MacPherson; Lauren DeBrouse; Giovanni Colacicco; Shaun M Flynn; Sophie Masneuf; Kristen E Pleil; Chia Li; Catherine A Marcinkiewcz; Thomas L Kash; Ozge Gunduz-Cinar; Marguerite Camp Journal: Nat Neurosci Date: 2012-09-02 Impact factor: 24.884
Authors: Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman Journal: Genome Biol Date: 2002-06-18 Impact factor: 13.583
Authors: R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman Journal: Int Rev Neurobiol Date: 2016-03-21 Impact factor: 3.230
Authors: Gerald A Deehan; Christopher P Knight; R Aaron Waeiss; Eric A Engleman; Jamie E Toalston; William J McBride; Sheketha R Hauser; Zachary A Rodd Journal: Alcohol Alcohol Date: 2016-06-15 Impact factor: 2.826
Authors: Robert A Waeiss; Christopher P Knight; Sheketha R Hauser; Lauren A Pratt; William J McBride; Zachary A Rodd Journal: Psychopharmacology (Berl) Date: 2019-02-13 Impact factor: 4.530
Authors: M G LeSage; M Staley; P Muelken; J R Smethells; I Stepanov; R I Vogel; P R Pentel; A C Harris Journal: Drug Alcohol Depend Date: 2016-09-01 Impact factor: 4.492
Authors: Gerald A Deehan; Sheketha R Hauser; Bruk Getachew; R Aaron Waeiss; Eric A Engleman; Christopher P Knight; William J McBride; William A Truitt; Richard L Bell; Zachary A Rodd Journal: Psychopharmacology (Berl) Date: 2018-07-24 Impact factor: 4.530
Authors: C E Van Skike; S E Maggio; A R Reynolds; E M Casey; M T Bardo; L P Dwoskin; M A Prendergast; K Nixon Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2015-11-12 Impact factor: 5.067